ClinicalTrials.gg

Program

apalutamide

Also written as “Apalutamide”, “JNJ-56021927” and “ARN-509”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Salivary Gland Neoplasms, led by 2 companies.

Furthest: phase 4, since Sep 26, 201928 company-led studies, 11 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson2711 open or runningphase 4since Sep 26, 2019Jul 27, 2010Dec 1, 2026phase 3 · NCT03767244
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead

Also a collaborator on its studies: Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Jul 27, 2010.

  1. Aug 21, 2015Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT02531516 · 1,503 enrolled · United States, Argentina, Belgium and more
  2. Oct 15, 20152 phase 1 studiesJohnson & Johnson · NCT02578797, NCT02592317
  3. Jun 29, 2016Phase 1 study in HealthyJohnson & Johnson · NCT02835508 · 18 enrolled · Japan
  4. Sep 15, 2016Phase 2 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT02906605 · United States
  5. Oct 4, 2016Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT02924766 · 34 enrolled · United States, Canada
  6. May 2, 2018Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT03523442 · 19 enrolled · China
  7. Dec 5, 2018Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT03767244 · 2,517 enrolled · United States, Argentina, Australia and more
  8. Jan 11, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03802682 · 12 enrolled · Belgium
  9. Sep 26, 2019Phase 4 study in Prostatic NeoplasmsJohnson & Johnson · NCT04108208 · 75 enrolled · China
  10. Nov 5, 2019Phase 1 study in Hepatic ImpairmentJohnson & Johnson · NCT04154774 · 18 enrolled · United States
  11. Mar 26, 2020Phase 2 study in Salivary Gland NeoplasmsJohnson & Johnson · NCT04325828 · 31 enrolled · Japan
  12. Sep 17, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04557059 · 691 enrolled · United States, Australia, Austria and more
  13. Dec 7, 2020Sumitomo Pharma's first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
  14. May 23, 2023Phase 3 study in Metastatic Castrate-sensitive Prostate CancerJohnson & Johnson · NCT05884398 · 420 enrolled · United States, Australia, Brazil and more

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT03767244
  2. Mar 1, 2027Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT02531516
  3. Aug 27, 2029Primary completion: phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04557059

TargetBeta

AR →read by rule
“A small molecule and androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05884398Metastatic Castrate-sensitive Prostate Cancer · United States, Australia, Brazil and more3Active, not recruitingJohnson & JohnsonOct 12, 2026420
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedSumitomo PharmaMay 28, 202448
NCT04557059Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingJohnson & JohnsonAug 27, 2029691
NCT04325828Salivary Gland Neoplasms · Japan2Active, not recruitingJohnson & JohnsonJun 9, 202131
NCT04154774Hepatic Impairment · United States1CompletedJohnson & JohnsonFeb 10, 202518
NCT04108208Prostatic Neoplasms · China4CompletedJohnson & JohnsonJun 1, 202375
NCT03802682Healthy · Belgium1CompletedJohnson & JohnsonApr 11, 201912
NCT03767244Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonDec 1, 20262,517
NCT03523442Prostatic Neoplasms · China1Active, not recruitingJohnson & JohnsonJul 9, 201919
NCT02924766Prostatic Neoplasms · United States, Canada1CompletedJohnson & JohnsonJul 18, 201934
NCT02906605Prostatic Neoplasms, Castration-Resistant · United States2WithdrawnJohnson & JohnsonSep 20180
NCT02835508Healthy · Japan1CompletedJohnson & JohnsonDec 201618
NCT02592317Prostatic Neoplasms, Castration-Resistant · Moldova, Spain1Active, not recruitingJohnson & JohnsonNov 7, 201623
NCT02578797Prostatic Neoplasms · United States, Canada, Moldova, Republic of and more1CompletedJohnson & JohnsonSep 20, 201645
NCT02531516Prostatic Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingJohnson & JohnsonMar 1, 20271,503
NCT02524717Hepatic Impairment · United States1CompletedJohnson & JohnsonFeb 9, 201724
NCT02489318Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonSep 7, 20201,052
NCT02257736Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonMar 19, 2018982
NCT02230033Healthy · United States1CompletedJohnson & JohnsonDec 201445
NCT02162836Prostatic Neoplasms, Castration-Resistant · Japan1CompletedJohnson & JohnsonMay 27, 20196
NCT02160756Healthy1CompletedJohnson & JohnsonNov 201475
NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more1Active, not recruitingJohnson & JohnsonJun 27, 201657
NCT02031666Healthy · United States1CompletedJohnson & JohnsonApr 2014120
NCT01946204Prostatic Neoplasms · United States, Australia, Austria and more3Active, not recruitingJohnson & JohnsonMay 19, 20171,207
NCT01822041Healthy · Netherlands1CompletedJohnson & JohnsonJun 201312
NCT01792687Prostatic Neoplasms · United States1CompletedJohnson & JohnsonMay 10, 20146
NCT01790126Prostatic Neoplasms · United States2CompletedJohnson & JohnsonMar 1, 201990
NCT01171898Prostatic Neoplasms · United States2CompletedJohnson & JohnsonAug 20, 2012127

How it is read

Names in the registry

  • “Apalutamide”, 18 entries
  • “JNJ-56021927”, 4 entries
  • “ARN-509”, 3 entries
  • “JNJ 56021927”, 1 entry
  • “apalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.